Literature DB >> 2579718

Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach.

H Battifora, M I Kopinski.   

Abstract

The authors investigated the expression of keratin, carcinoembryonic antigen (CEA), and an epithelial marker derived from milk fat globule membranes in 12 mesotheliomas and 100 diverse adenocarcinomas with immunohistochemical methods. The authors employed a monoclonal antibody to keratin designated as AE1, as well as the following commercially available antisera: rabbit anti-whole human keratin, rabbit anti-CEA, and a monoclonal antibody to an epithelial factor designated as MFG-2. Expression of keratin was found in all the mesotheliomas and adenocarcinomas with antibody AE1 as well as with the rabbit antiserum; CEA was detectable in 65% of the adenocarcinomas but two mesotheliomas also reacted weakly. With antibody MFG-2, positive results were obtained in 85% of the adenocarcinomas and in none of the mesotheliomas. All of 64 (100%) breast-, lung- and ovary-derived adenocarcinomas immunostained positively with antibody MFG-2. This is of particular significance because pulmonary and ovarian adenocarcinoma frequently may be indistinguishable clinically and histologically from epithelial mesothelioma. The authors conclude that antikeratin antibodies are not useful in the distinction of adenocarcinoma from mesothelioma. Because of its greater sensitivity and specificity, MFG-2 is superior to CEA in this differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579718     DOI: 10.1002/1097-0142(19850415)55:8<1679::aid-cncr2820550812>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Malignant mesothelioma.

Authors:  R Rudd
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

2.  New marker for mesothelioma: an immunoperoxidase study.

Authors:  A Donna; P G Betta; D Bellingeri; A Marchesini
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

3.  Immunohistochemistry in the diagnosis of malignant mesothelioma.

Authors:  M Pfaltz; B Odermatt; B Christen; J R Rüttner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

Authors:  K Sheibani; H Battifora; J S Burke
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

5.  Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.

Authors:  T Kawai; S D Greenberg; L D Truong; C A Mattioli; M Klima; J L Titus
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

Review 6.  Value of CD15 immunostaining in diagnosing Hodgkin's disease: a review of published literature.

Authors:  P A Hall; A J D'Ardenne
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

7.  Subcutaneous metastasis of peritoneal mesothelioma diagnosed by fine-needle aspiration.

Authors:  Lina Pappa; Melpomeni Machera; Eleni Tsanou; Constantina Damala; Dimitrios Peschos; Maria Bafa; Vassiliki Malamou-Mitsi
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

8.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

9.  The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).

Authors:  C A Szpak; W W Johnston; V Roggli; J Kolbeck; S C Lottich; R Vollmer; A Thor; J Schlom
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

10.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.